Iovance Biotherapeutics, Inc. (IOVA) incurred a loss of 34 cents per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 37 cents. In the year-ago quarter, the company reported a loss of 47 cents.During the quarter, the company generated total revenues of $31.1 million — entirely from the product sales of its two marketed drugs. The reported sales beat the Zacks Consensus Estimate of$22.6 million. In the year-ago quarter, Iovance recorded total revenues of $0.2 million.Qua ...